These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38860864)

  • 21. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
    Pehlivan UA; Somay E; Yilmaz B; Besen AA; Mertsoylu H; Selek U; Topkan E
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment Systemic Immune-Inflammation Index Predict Needs for Teeth Extractions for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy.
    Yilmaz B; Somay E; Selek U; Topkan E
    Ther Clin Risk Manag; 2021; 17():1113-1121. PubMed ID: 34703240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up.
    Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ
    BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent chemoradiotherapy plus anlotinib vs. concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: An interim analysis of a multicenter randomized controlled trial.
    Chen K; Xu G; Liang Y; Liang P; Gao W; Li Z; Liang W; Tao Z; Chen J; Hu X; Xu Y
    Oncol Lett; 2023 Sep; 26(3):392. PubMed ID: 37600344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis.
    Dechaphunkul A; Danchaivijitr P; Jiratrachu R; Dechaphunkul T; Sookthon C; Jiarpinitnun C; Paoin C; Setakornnukul J; Suktitipat B; Pattaranutaporn P; Ngamphaiboon N
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):51-61. PubMed ID: 35394108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of induction chemotherapy on nutrition status in locally advanced nasopharyngeal carcinoma: a multicentre prospective study.
    Miao J; Wang L; Ong EHW; Hu C; Lin S; Chen X; Chen Y; Zhong Y; Jin F; Lin Q; Lin S; Hu X; Zhang N; Wang R; Wang C; Guo X; Yit NLF; Shi H; Tan SH; Mai H; Xie C; Chua MLK; Zhao C
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):815-825. PubMed ID: 36872457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
    Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
    Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
    Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study.
    Huang L; Yang Z; Kang M; Ren H; Jiang M; Tang C; Hu Y; Shen M; Lin H; Long L
    Technol Cancer Res Treat; 2023; 22():15330338231160619. PubMed ID: 37094106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
    Wang L; Zhuang H; Xu X; Zhou J; Jiao Y
    Front Oncol; 2023; 13():1129649. PubMed ID: 36814816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
    Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
    Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
    PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor angiogenesis at baseline identified by
    Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
    J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
    Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
    Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 40. The predictive value of pretreatment hemoglobin-to-platelet ratio on osteoradionecrosis incidence rates of locally advanced nasopharyngeal cancer patients managed with concurrent chemoradiotherapy.
    Yilmaz B; Somay E; Topkan E; Kucuk A; Pehlivan B; Selek U
    BMC Oral Health; 2023 Apr; 23(1):231. PubMed ID: 37081475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.